Drug Class and Categories: Nivolumab belongs to the class of immunotherapy agents and is categorized as a monoclonal antibody. It is used in the field of oncology to treat various types of cancers.

Active Ingredient and Other Names:

• Active Ingredient: Nivolumab

• Popular and Other Names: Opdivo (brand name), Nivolumab Injection

Mode of Action: Nivolumab works by blocking the PD-1 (programmed death-1) receptor on immune cells. PD-1 is a checkpoint protein that inhibits immune responses against cancer cells. By inhibiting PD-1, Nivolumab enhances the immune system's ability to recognize and attack cancer cells, thus improving the body’s immune response to tumors.

How to Use It:

• Administration: Nivolumab is administered via intravenous infusion.

• Usage: Infusions are typically given in a clinical setting, usually every 2 to 4 weeks, depending on the type of cancer and individual treatment plan.

Recommended Dosage:

• Non-Small Cell Lung Cancer (NSCLC): 240 mg every 2 weeks or 480 mg every 4 weeks.

• Melanoma: 240 mg every 2 weeks or 480 mg every 4 weeks.

• Renal Cell Carcinoma: 240 mg every 2 weeks or 480 mg every 4 weeks.

• Hodgkin Lymphoma: 240 mg every 2 weeks.

• Other Cancers: Dosage may vary based on specific cancer type and treatment response.

Directions:

• Infusion Protocol: Administer Nivolumab as an intravenous infusion over a period of 30 minutes.

• Preparation: Follow the guidelines for preparation and dilution provided by the manufacturer. Ensure all equipment and infusion procedures are sterile.

Cautions:

• Pregnancy and Breastfeeding: Use Nivolumab with caution if pregnant or breastfeeding. Consult with your healthcare provider about the risks and benefits.

• Pre-existing Conditions: Inform your healthcare provider about any history of autoimmune diseases, organ transplants, or infections.

• Immune-Related Adverse Events: Monitor for signs of immune-related adverse effects, such as pneumonitis, colitis, hepatitis, endocrinopathies, and nephritis.

Manage Side Effects:

• Common Side Effects: Fatigue, rash, diarrhea, and nausea.

• Severe Side Effects: Seek immediate medical attention for symptoms of severe immune reactions, such as persistent cough, severe abdominal pain, jaundice, or signs of an allergic reaction.

Guidelines:

• Storage: Store Nivolumab in the refrigerator (2°C to 8°C). Do not freeze. Keep it in its original packaging to protect from light.

• Missed Dose: If a dose is missed, contact your healthcare provider to reschedule the infusion as soon as possible.

• Overdose: In case of overdose, seek emergency medical assistance. Monitor and manage adverse effects according to clinical guidelines.

Frequently Asked Questions (FAQs):

1. What is Nivolumab used for?
   Nivolumab is used to treat various cancers including non-small cell lung cancer, melanoma, renal cell carcinoma, and Hodgkin lymphoma by enhancing the body's immune response against cancer cells.

2. How is Nivolumab administered?
   Nivolumab is given as an intravenous infusion in a clinical setting. The infusion is typically administered every 2 to 4 weeks.

3. What are the common side effects of Nivolumab?
   Common side effects include fatigue, rash, diarrhea, and nausea. Severe immune-related adverse effects may also occur.

4. What should I do if I miss a dose of Nivolumab?
   Contact your healthcare provider immediately to reschedule the infusion. It is important to adhere to the treatment schedule.

5. Are there any special precautions while using Nivolumab?
   Yes, monitor for immune-related adverse effects and inform your healthcare provider about any pre-existing conditions or symptoms of severe reactions.

6. Can Nivolumab be used in combination with other treatments?
   Nivolumab can be used alone or in combination with other therapies, such as other checkpoint inhibitors or chemotherapy, depending on the cancer type and treatment plan.